Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

ASH 2015

Published: 6 Dec 2015

Views: 2137

Rating:

Save

Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany

Prof Stilgenbauer presents, at a press conference at ASH 2015, results of the pivotal international phase II study.

Venetoclax monotherapy induces deep remissions, including complete remission and undetectable mrd, in ultra-high risk relapsed/refractory chronic lymphocytic leukaemia with 17p deletion.

Read the news story and watch the video interview for more information.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

GIST tumours and soft tissue sarcomas

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA

GIST tumours and soft tissue sarcomas ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )

A patient-reported questionnaire may eliminate the need for an ophthalmic exam...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

Importance of MRD in newly developed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

Importance of MRD in newly developed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel...

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

More from ecancer